Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Endocrine 1

Conditions

Breast Neoplasms 2Neoplasms by Site 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Breast Diseases 1Advanced Metastatic Breast Cancer 1

Interventions

Trastuzumab 9Paclitaxel 8Capecitabine 8trastuzumab deruxtecan 7Fulvestrant 7pertuzumab 5eribulin 5Gemcitabine 5Cyclophosphamide 5130-nm albumin-bound paclitaxel 5Doxorubicin 4Carboplatin 4Ado-Trastuzumab Emtansine 4sacituzumab govitecan 3ribociclib 3Vinorelbine 3Epirubicin 3Docetaxel 3selpercatinib 2pembrolizumab 2palbociclib 2olaparib 2neratinib 2larotrectinib 2exemestane 2capivasertib 2abemaciclib 2Letrozole 2Fluorouracil 2Anastrozole 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has announcements × ribociclib × Breast × Clear all
NCT03701334 2026-04-01

NATALEE

Novartis

Phase 3 Active not recruiting
5,101 enrolled 1 FDA
Breast

Breast Neoplasms

NCT02278120 2024-03-12

MONALEESA-7

Novartis

Phase 3 Completed
672 enrolled 16 charts 1 FDA
Breast

Advanced Metastatic Breast Cancer

NCT02422615 2023-11-30

MONALEESA-3

Novartis

Phase 3 Completed
726 enrolled 17 charts 1 FDA
BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡